New
Retatrutide 20 mg
149,00 €
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Body weight reduction of up to 24% in Phase II trials; the most potent in its class.
- Greater reduction in body fat compared to tirzepatide.
- Improved glycemic control through multiple mechanisms.
- Improvement in cardiovascular risk factors.
- Potential for treating NASH and reducing liver fat.
Description
Retatrutide
Weight Loss / Metabolism
MECHANISM OF ACTION
Triple agonist: GLP-1R for satiety and insulin secretion; GIPR for glucose-dependent insulin secretion and energy expenditure through activation of brown adipose tissue; and the glucagon receptor for energy expenditure, lipolysis, and normalization of hepatic glucose production. The GIP base conjugated with a fatty acid extends the half-life. Triple-receptor activation provides a superior metabolic effect compared to dual agonists.
KEY BENEFITS
- Body weight reduction of up to 24% in Phase II trials; the most potent in its class.
- Greater reduction in body fat compared to tirzepatide.
- Improved glycemic control through multiple mechanisms.
- Improvement in cardiovascular risk factors.
- Potential for treating NASH and reducing liver fat.
SIDE EFFECTS AND SAFETY
Prominent gastrointestinal side effects, such as nausea, vomiting, and diarrhea. Its action on the glucagon receptor leads to increased energy expenditure and possible mild hyperglycemia at the start of treatment. Titration minimizes intolerance.
RESEARCH AND CLINICAL NOTES
Jastreboff et al. (NEJM 2023): 24.2% reduction in body weight at 48 weeks with the highest dose; the highest result to date in a weight-loss drug trial. Phase III TRIUMPH trial ongoing. Compound under development by Eli Lilly.
TARGET PROFILE:
Obesity Medicine, Endocrinology, and Weight Loss.
Additional information
| Weight | ,26 kg |
|---|
You may also like…
Hot
Algal Oil Omega 3 EPA/DHA, 100 capsules
- Vegan source of Omega-3: Schizochytrium microalgae oil, a sustainable alternative to fish oil.
- Cardiovascular health: DHA and EPA help reduce triglycerides, improve circulation, and control blood pressure.
- Brain and cognitive wellness: Supports memory, concentration, and prevents cognitive decline.
- Eye health: DHA is an essential component of the retina, helping maintain optimal vision.
- Anti-inflammatory properties: Alleviates symptoms of arthritis and other chronic inflammatory diseases.
- Suitable for vegans: Free from gluten, lactose, and preservatives.
Related products
New
AOD-9604
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Targeted fat loss without IGF-1-mediated growth effects.
- No effect on blood glucose or insulin sensitivity.
- Fat reduction is well tolerated in patients with metabolic disorders and diabetes.
- It supports body recomposition when combined with exercise.
- Being investigated for cartilage repair (TGA approval in Australia for OA).
New
CJC-1295 5 mg without DAC + IPA 5 mg
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Synergistic optimization of endogenous GH secretion.
- Reference GH Peptide Stack for Body Composition.
- Increased lean body mass, fat loss, and recovery.
- Maintenance of the pulsatile rhythm of GH, with lower long-term risk.
- Ipamorelin's selectivity minimizes the increase in cortisol and prolactin.
New
Kisspeptin
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- It stimulates the LH surge to optimize testosterone levels in men.
- Activation of the HPG axis without suppression by exogenous testosterone.
- Improvement of libido via the central dopaminergic pathway.
- Supporting fertility through GnRH pulse restoration.
- Potential in hypogonadotropic hypogonadism.
- Emerging: Support for cardiac collagen and neuroprotection.
MOTS-c
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- AMPK-mediated metabolic improvements, including glucose and fat utilization.
- Mimetic properties of exercise.
- Anti-inflammatory and anti-aging effects.
- Supports bone metabolism through osteoblastic activity.
- Protection against age-related physical decline.
- Potential for research on T2DM and obesity management.
New
Retatrutide 10 mg
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Body weight reduction of up to 24% in Phase II trials; the most potent in its class.
- Greater reduction in body fat compared to tirzepatide.
- Improved glycemic control through multiple mechanisms.
- Improvement in cardiovascular risk factors.
- Potential for treating NASH and reducing liver fat.
New
Semax
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Cognitive improvement: memory, attention, and processing speed.
- Neuroprotection in stroke, traumatic brain injury, and cerebral ischemia.
- Upregulation of BDNF/NGF for neuroplasticity.
- Anxiolytic and antidepressant properties.
- Immune modulation.
- Excellent safety profile: non-addictive and with minimal side effects.
New
TB500
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Systemic repair and regeneration of soft tissues.
- Accelerated wound healing and scar reduction.
- Improved tissue flexibility and reduced inflammation.
- Cardiac protection and myocardial repair.
- Eye repair in research on corneal regeneration.
- Protection of renal podocytes.
New
Tirzepatide
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Body weight reduction of up to 22.5% in SURMOUNT-1.
- A 2.0–2.3% reduction in HbA1c in the SURPASS program.
- Superior glycemic control compared with semaglutide in a direct comparative trial.
- Reduction in triglycerides and LDL.
- Improvement in sleep apnea in the SURMOUNT-OSA trial.
- Approved by the FDA for T2DM as Mounjaro and for obesity as Zepbound.
